| Accession number;06A0654480 |
| Title;Review/Advances in Neurological Therapeutics (2005). Stroke. |
| Author;YAMAGUCHI SHUHEI(Shimane Univ.) BOKURA HIROKAZU(Shimane Univ.) TAKAHASHI KAZUO(Shimane Univ.) |
Journal Title;Neurological Therapeutics
|
Journal Code:X0110A
|
ISSN:0916-8443
|
|
VOL.23;NO.4;PAGE.357-360(2006)
|
| Figure&Table&Reference;REF.30 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;A potent thrombolysis agent, t-PA, was approved by the Japanese government for the treatment of acute cerebral thrombosis in October 2005. This is an epoch-making event for the stroke treatment in Japan and has been waited for long time. However, there are several limitations for the administration of t-PA to acute stroke because of safety. Several attempts to extend the time window for the treatment were undertaken, such as optimal patient selection by using some MRI parameters. Patients with minor stroke or over 80 years old can be also candidates for thrombolysis with t-PA in future. The combination of t-PA and transcranial sonography may be a useful option for the treatment of middle cerebral artery occlusion. Several studies reported the efficacy of the combined therapy of t-PA fibrinolysis and Abciximab platelet inhibition with additional transluminal angioplasty for improving recanalization and neurological ourcome. Aspirin is currently a gold standard drug for the secondary prevention of ischernic stroke. Since the risk reduction by aspirin is no more than 25%, combination therapy with other drug such as dipyridamole, clopidogrel or cilostazole has been assessed with favorable results in selected stroke patients. Stantin administration is reported to be useful not only for prevention of ischernic stroke recurrence but also for neurological recovery after stroke onset. Botulinum toxin A injections have been used successfully in the treatment of post-stroke foot spasticity, associated pain, gait speed and function. This treatment is favorable for economic reason as well as safety compared to oral antispastic drugs. Serotonin reuptake inhibitors have become the first choice for the treatment of poststroke depression these days, as demonstrated in several RTC studies.... (author abst.) |
